Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Understanding genotype to predict phenotype
- The path from genotype to phenotype
- A better understanding of phenotype is required
- Medicine has always been "personalized"
- The "omics" (molecules) we should measure
- Proteomics
- A technology to address the proteome complexity
- SomaLogic's version of SELEX - SOMAmers
- The privileged 5 position of pyrimidines
- "Pull downs" show SOMAmer specificity
- Crystal structures (1)
- Crystal structures (2)
- Crystal structures (3)
- Crystal structures (4)
- SOMAscan proteomic assay- from protein to DNA
- SOMAmers are measured by DNA techniques
- SOMAscan today
- Using SOMAscan (lung cancer)
- Using SOMAscan (non-small cell lung cancer)
- Lung cancer serum biomarkers
- Diagnostic performance of 7-marker classifier
- Using SOMAscan (cardiovascular risk)
- Using SOMAscan (pre-term birth)
- Using SOMAscan (pancreatic cancer)
- Using SOMAscan (Mesothelioma)
- Using SOMAscan - diagnostic pipeline
- Future goals-wellness chip, longitudinal monitoring
- Longitudinal blood tests can detect cancer early
- Longitudinal blood tests can facilitate Wellness
- Conclusions
- One last thought
- Acknowledgements
Topics Covered
- The proteomic revolution
- Proteomics is the best measure of phenotype (biomarkers)
- Slow Off-rate Modified Aptamers (SOMAmers) are breakthrough protein binding reagents
- SOMAmers are multiplexed to perform SOMAscan assay, which measures >1000 proteins in small sample volumes using DNA measurement tools to identify and quantify proteins bound by SOMAmers
- Applications of SOMAscan to date include finding valid protein biomarkers for lung cancer, cardiovascular risk, pre-term birth, pancreatic cancer, mesothelioma, and many other diseases and conditions
- Ability to do comprehensive longitudinal proteomics studies will revolutionize medicine
Talk Citation
Gold, L. (2022, May 29). The proteomic revolution [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/MGMP1794.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Larry Gold has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Update Available
The speaker addresses developments since the publication of the original talk. We recommend listening to the associated update as well as the lecture.
- Full lecture Duration: 54:31 min
- Update Interview Duration: 23:19 min
A selection of talks on Cancer
Transcript
Please wait while the transcript is being prepared...
0:00
Today I'm going to tell you about the proteomic revolution.
As it says on slide 1, my name is Larry Gold,
the CEO and Chairman of the Board of SomaLogic company in Boulder, Colorado.
I'm also a part-time faculty member at the University of Colorado in Boulder,
where I've been on the faculty since 1970.
Let's just jump into the proteomic revolution.
0:30
For the next few slides,
I'm going to try to put into context proteomics
(the topic for today's talk), in the context of other '-omices'.
I'll start by showing a way of thinking
about what happened when the human genome was sequenced.
Of course it's still being sequenced, but what has happened is that
everyone is excited that with that genome sequence we'll able to
understand medicine, and health, and wellness, and aging.
A lot of unbelievable things.
In a way that's true.
In a way, having the genotype may be equivalent to having anatomy 200 years ago.
There's this notion that knowledge of something
as basic as the genome will be useful, and it is
and has been, and will continue to be.
What I want to talk about is the difference between knowing the genotype
(which is really a lot about the ensuing 100 years
of your life), and these other kinds of things that have more to do
with phenotype.
Slide number 3 is exactly like slide number 2, except there's a black box in the middle.